Abstract The RAS/RAF/MEK/ERK pathway has been reported to be activated in over 80% of
all cutaneous melanomas, making it the focus of many scientific studies in the melanoma …

The development of novel treatments that selectively inhibit the RAS-RAF-MAPK pathway
represents a milestone in the history of melanoma treatment. BRAF mutations occur in …

The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in
the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF …

The past decade has seen significant advances in our understanding of the cell signaling
pathways that drive melanoma in humans. These studies have demonstrated that the …

Melanoma is an aggressive form of skin cancer that causes the greatest number of skin
cancer-related deaths worldwide. In its early stages malignant melanoma can be cured by …

The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its
progression have opened a new era in the treatment of this tumor. Vemurafenib was the first …

Inhibition of the BRAF/MAPK pathway belongs to the standard therapies for patients with
activating BRAF V600E/K mutations. However, even in well-responding tumors, anti …

Since the discovery of activating mutations in the BRAF oncogene in melanoma, there has
been remarkable progress in the development of targeted therapies for unresectable and …

Abstract The RAS-RAF-MEK-ERK pathway is considered to be the most important signal
transduction pathway in melanoma, and alterations in this pathway via various genetic …

Simple Summary The management of unresectable and metastatic cutaneous melanoma
has substantially improved with the introduction of molecular targeted therapy (BRAF and …